   |
|
CURRENT PERSPECTIVE |
|
| Year : 2017 | Volume
: 62
| Issue : 4 | Page : 392-394 |
|
| Propionibacterium acnes and the Th1/Th17 Axis, implications in acne pathogenesis and treatment |
|
|
Kabir Sardana, Gunjan Verma
Department of Dermatology & STD, PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi, India
| Date of Web Publication | 10-Jul-2017 |
Correspondence Address:
Gunjan Verma
PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.IJD_483_16
|
|
 Abstract | | |
Acne vulgaris is one of the most commonly seen conditions and the immunological link is a topic of active research. Recently, the Th17 pathway has been found to play a pivotal role in acne. The adaptive immune response toward Propionibacterium acnes leads to activation of Th17 axis. Consequently, the Th17 cytokines (IL-17, IL-1 β, IL-6, and tumor growth factor, in turn, activate the various pathogenic steps in acne. Drugs such as Vitamin D3 and isotretinoin which target the Th17 pathway may offer an additional pathway for their therapeutic response.
Keywords: Acne, IL 17, Propionibacterium acnes, Th1/Th17 axis
How to cite this article:
Sardana K, Verma G. Propionibacterium acnes and the Th1/Th17 Axis, implications in acne pathogenesis and treatment. Indian J Dermatol 2017;62:392-4 |
How to cite this URL:
Sardana K, Verma G. Propionibacterium acnes and the Th1/Th17 Axis, implications in acne pathogenesis and treatment. Indian J Dermatol [serial online] 2017 [cited 2023 Jun 1];62:392-4. Available from: https://www.e-ijd.org/text.asp?2017/62/4/392/210089 |
What was known?
It has been estabilished that Acne is a disorder wherein apart from the minor role of P.acnes, it is the inflammation, hypercornification and sebaceous gland that are fundamental to its causation. It is believed that the sebaceous gland with its multiple receptors is the crucial organ in the skin.
| Introduction | |  |
Although Propionibacterium acnes had been proposed to play a role in acne, 50 years after it was discovered, its role was cast into doubt with the isolation of this organism from normal human skin.[1] Thus in the context of the increasing levels of resistance, as reported by an Indian study that found high resistance to clindamycin and macrolides (azithromycin), it was proposed that it would be best to avoid drugs that inhibit P. acnes and use drugs such as isotretinoin, zinc, and oral subantimicrobial doses of antibiotics (cyclines) to treat acne.[2],[3] Novel molecules are being discovered that work by inhibiting P. acnes that do not preclude to resistance, even though some of them have been studied in vitro. [3] Recently, three studies that focus on the role of adaptive immunity, specifically Th17 cells, brings the focus back on the role of P. acnes in acne.[4],[5],[6]
| Immune Response in Acne | | |
It had been postulated that immunogenic P. acnes proteins released into the follicle could be processed by Langerhans cells, which could, in turn, present these antigens to CD4+ T-cells in local lymph nodes, via toll-like receptor 2 (TLR2) [Figure 1].[7] Histological studies found that CD4+ T-cells are the major leukocytes in the early (6–72 h) inflammatory infiltrates in acne lesions, with a small portion of CD1+ dendritic cells. Neutrophils emerge when the 24 h and 72 h lesions are biopsied, which are then clinically identified as pustules.[8] CD8+ cells infiltrate the lesion later. These histological findings can now be explained by the Th17 axis a key component of the adaptive immune response [Figure 1].[9] | Figure 1: Mechanisms of Th1/Th17 cell induction in acne. Propionibacterium acnes in conjunction with toll-like receptor 2 receptors stimulate the CD4 naïve cells to differentiate into Th1 and Th17 cells. Tumor growth factor-beta induce regulatory T cells and Th17 cells via the induction of FoxP3 and RORC. Inflammatory cytokines, such as IL-6, IL-21, and IL-23, initiates Th17 axis. The effector cytokines released by Th17 cells include IL-17, IL-21, IL-22, and CCL20, which act on both immune and nonimmune cells and mediate several functions. APC: Antigen presenting cells; B: B cell; DC: Dendritic cell; EC: Endothelial cell; EpC: Epithelial cell
Click here to view |
Studies that assess the cytokine response, should ideally test the expression of TLR2, TLR4, IL-8, IL-1beta, tumor necrosis factor-alpha (TNF-α) and IL-6, which is largely indicative of innate immune response. The adaptive immune response is assessed by IL-12 β, interferon gamma (IFNγ), IL-23A, IL-17A, and IL-22. Kistowska et al. found P. acnes-reactive Th17 and Th17/Th1 cells in the peripheral blood of patients suffering from acne and noted that while Th1 cells could be induced in only 40% of the tested donors; Th17 and Th17/Th1 cells could be induced by P. acnes in 100% of them.[6] This point to a Th1/Th17 axis in acne. The cytokines that play a role in the Th1/Th17 axis, including IL-1 β, IL-6 and tumor growth factor-beta (TGF-β), have been consistently found in acne lesions.[4],[5],[6] Agak et al. and Kistowska et al. had proposed that IL-23, does not play a role in this Th17 response.[5],[6] A recent study though found that IL-23 p19 is an important component in the immune response. In addition, elevated levels of IL-22, IL-20, IL-1, IL-6, TNF-α, and TGF-β important in Th17 cell activation have been noted in acne lesions.[4] Elevated serum levels of anti-inflammatory cytokine IL-10, Treg cells and increased number of Foxp3+ cells in the papillary dermis, are an additional finding, the last of which (Tregs), prevent autoimmunity and suppress immune responses.[4]
A contrarian view was suggested by a study that studied the role of isotretinoin on adaptive immune response and observed significant downregulation of pro-inflammatory mediators IL-1 β and TLR2, as well as upregulation of antimicrobials S100A7 and lipocalin-2 (LCN-2) messenger RNA (mRNA) in the uninvolved skin in the acne patients. Remarkably, there was a lack of an effect on the level of Treg marker FOXP3 mRNA.[10]
| Clinical Implications | | |
The implications of this research are manifold. First, this represents a new outlook to the pathogenesis of acne, wherein the Th17 pathway is now increasingly being recognized and can explain the histological findings and inflammation seen in acne.[4],[5],[6],[9] This is consequent to the Th17 effector cytokines, IL-17 and IL-22, which have the capacity to stimulate the production of various antimicrobial peptides and induce the production of neutrophil-recruiting chemokines such as IL-8 (CXCL8) in epithelial cells [Figure 1].[9] The Th17 cells also increases the specter of chronicity of disease, much like psoriasis, though in the case of acne, individual lesions do eventually resolve. This is consequent to the increased expression of IL-10 and Tregs that demarcate the inflammation of a single acne lesion efficiently from the beginning.[4] The resolution of lesions can be understood in the light of the interplay of cytokines that mediate the Th17 axis. It has been shown that the combination of TGF-β and IL-21 is sufficient to induce the differentiation of human Th17 cells from naïve T cells, and IL-1 and IL-6 are important for enhancing the expansion of differentiated and memory Th17 cells.[9] However, in the absence of inflammation, the prominent TGF-β alone induces Foxp3, leading to the generation of iTregs that maintain immune tolerance along with nTregs.[9] The rupture of the follicular walls and the decrease in the inflammatory cytokines can explain the resolution of individual lesions in acne.
There are therapeutic implications of the Th17 pathway, as drugs that inhibit this axis can have an enhanced role in the treatment of acne. These include dihydroxyvitamin D3, retinoids, Vitamin A and zinc, most of which have proven in vivo efficacy in acne.[4],[5],[6],[9] Retinoic acid can regulate reciprocally Tregs and Th17 through TGF-β-dependent generation of Foxp3, a mechanism that may be of importance in the treatment of acne by isotretinoin.[9],[11]
Isotretinoin, has anti-inflammatory properties, downregulating TLR2 expression on monocytes and neutrophil migration.[12],[13] Importantly, they inhibit inflammatory Th17 and promote regulatory T-cell (Treg) responses.[14] A pilot study on gene expression from India found that with low dose isotretinoin, there was a upregulation in the expression of some prime genes such as LCN2, KRT23, and SERPINA3, which accounted for the initiation of the immune response against the pathogens causing acne.[15] The significant aspect of most of the salient studies assessing the role of isotretinoin on gene expression is that low dose isotretinoin, through upregulation of apoptotic proteins such as TRAIL, IGFBP3, and LCN2 suppresses excessive sebum production associated with pro-inflammatory NLRP3 inflammasome activation.[16]
Furthermore, the use of anti-IL-1 β and anti-IL-12/IL-23 may represent an efficient strategy for the targeting of Th17/Th1 cells. Active vaccination against IL-17 can replace the use of oral agents. A study has found that virus-like particles based vaccine against the IL-17 molecule is safe and effective in IL-17 mediated skin condition including acne vulgaris.[17]
Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome an inflammatory syndrome associated with acne has responded favorably to anti-IL-1 antagonists involved in blocking of IL-17.[18]
Importantly if this axis is crucial in acne, the dependence on antibiotics can be obviated that would ameliorate the specter of resistance which is at present a clear and present danger. This research, changes the focus, from P. acnes to sebocytes and inflammation, which is a heartening fact, as this might reduce the focus on antibiotics with their attendant issue of resistance which is at present a clear and present danger.[2],[3]
| Conclusion | | |
Th17 cells display considerable plasticity and Th17 cells are unstable and depending on the type of inflammation and cytokine milieu, Th17 cells can acquire a phenotype of other T-cell subsets, such as IL-17 + IFNγ + T cells and IL17 + IL-4 + T cells.[9] The discovery of Th17 cells in acne will have to be examined in a larger number of patients and lesions, in various types of acne, including the “difficult” acne cases, including the persistent, late onset, hormonal and resistant cases, to understand its role in acne. But it seems, that the focus is back on the role of P. acnes, as the adaptive immune response, as evidenced by the Th1/Th17 axis is as a direct consequence of the immunogenicity of the organism.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Evans CA, Smith WM, Johnston EA, Giblett ER. Bacterial flora of the normal human skin. J Invest Dermatol 1950;15:305-24.  [ PUBMED] |
| 2. | Sardana K, Gupta T, Kumar B, Gautam HK, Garg VK. Cross-sectional pilot study of antibiotic resistance in Propionibacterium Acnes strains in Indian acne patients using 16S-RNA polymerase chain reaction: A comparison among treatment modalities including antibiotics, benzoyl peroxide, and isotretinoin. Indian J Dermatol 2016;61:45-52. [ PUBMED] [Full text] |
| 3. | Sardana K, Gupta T, Garg VK, Ghunawat S. Antibiotic resistance to Propionobacterium acnes: Worldwide scenario, diagnosis and management. Expert Rev Anti Infect Ther 2015;13:883-96. |
| 4. | Kelhälä HL, Palatsi R, Fyhrquist N, Lehtimäki S, Väyrynen JP, Kallioinen M, et al. IL-17/Th17 pathway is activated in acne lesions. PLoS One 2014;9:e105238. |
| 5. | Agak GW, Qin M, Nobe J, Kim MH, Krutzik SR, Tristan GR, et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by Vitamin A and Vitamin D. J Invest Dermatol 2014;134:366-73. |
| 6. | Kistowska M, Meier B, Proust T, Feldmeyer L, Cozzio A, Kuendig T, et al. Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. J Invest Dermatol 2015;135:110-8. |
| 7. | Farrar MD, Ingham E. Acne: Inflammation. Clin Dermatol 2004;22:380-4. |
| 8. | Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988;118:651-9. |
| 9. | Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: Biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012;181:8-18. |
| 10. | Kelhälä HL, Fyhrquist N, Palatsi R, Lehtimäki S, Väyrynen JP, et al. Isotretinoin treatment reduces acne lesions but not directly lesional acne inflammation. Exp Dermatol 2016;25:477-8. |
| 11. | Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, et al. Retinoic acid increases Foxp3+regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008;181:2277-84. |
| 12. | Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012;132:2198-205. |
| 13. | Camisa C, Eisenstat B, Ragaz A, Weissmann G. The effects of retinoids on neutrophil functions in vitro. J Am Acad Dermatol 1982;6 4 Pt 2 Suppl:620-9. |
| 14. | Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007;317:256-60. |
| 15. | Jha D, Sardana K, Gautam HK. Regulation of gene expression by quantitative real time PCR in low dose isotretinoin treated acne patients. Gene Technol 2015;S1:001. |
| 16. | Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Invest 2008;118:1468-78. |
| 17. | Foerster J, Bachman M. Beyond passive immunization: Toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments. Nanomedicine (Lond) 2015;10:1361-9. |
| 18. | Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR. SAPHO syndrome: Current developments and approaches to clinical treatment. Curr Rheumatol Rep 2016;18:35. |
What is new?
- The Th 17 axis may mediate the inflammation in acne
- This may explain the chronicity of acne lesions
- Drugs that work on this pathway may be important to treat acne
- Isotretinoin probably mediates its action via the Th 17 axis
[Figure 1] |
|
| This article has been cited by | | 1 |
Serum level changes of inflammatory cytokines in patients with moderate to severe acne vulgaris treated with dual-wavelength laser |
|
| Yang Liu, Qilin Sun, Hui Xu, Gang Ma, Pinru Wu | | Chinese Journal of Plastic and Reconstructive Surgery. 2023; | | [Pubmed] | [DOI] | | | 2 |
Myrtus communis
and Celastrol enriched plant cell culture extracts control together the pivotal role of
Cutibacterium acnes
and inflammatory pathways in acne
|
|
| Céline Mias, Nathalie Chansard, Martine Maitre, Marie Florence Galliano, Lucile Garidou, Valerie Mengeaud, Sandrine Bessou-Touya, Hélène Duplan | | Journal of the European Academy of Dermatology and Venereology. 2023; 37(S2): 12 | | [Pubmed] | [DOI] | | | 3 |
Recent advances in understanding inflammatory acne: Deciphering the relationship between
Cutibacterium acnes
and Th17 inflammatory pathway
|
|
| Céline Mias, Valerie Mengeaud, Sandrine Bessou-Touya, Hélène Duplan | | Journal of the European Academy of Dermatology and Venereology. 2023; 37(S2): 3 | | [Pubmed] | [DOI] | | | 4 |
Network Pharmacology-Based Investigation on the Mechanism of the JinGuanLan Formula in Treating Acne Vulgaris |
|
| Noha Saleh Gholais, Chunrui Shi, Jing Zhang, Bei Liao, Rowida A. Albarmaqi, Xiaolong Tang, Leyuan Mi, Bashar Saad | | Evidence-Based Complementary and Alternative Medicine. 2022; 2022: 1 | | [Pubmed] | [DOI] | | | 5 |
Nano-Therapeutics to Treat Acne Vulgaris |
|
| Nayanika Chakraborty, Varsha Narayanan, Hemant K. Gautam | | Indian Journal of Microbiology. 2022; | | [Pubmed] | [DOI] | | | 6 |
MicroRNA Cross-Involvement in Acne Vulgaris and Hidradenitis Suppurativa: A Literature Review |
|
| Francesco Borgia, Lucia Peterle, Paolo Custurone, Mario Vaccaro, Giovanni Pioggia, Sebastiano Gangemi | | International Journal of Molecular Sciences. 2022; 23(6): 3241 | | [Pubmed] | [DOI] | | | 7 |
The Role of Skin Immune System in Acne |
|
| Ewelina Firlej, Wioleta Kowalska, Karolina Szymaszek, Jacek Rolinski, Joanna Bartosinska | | Journal of Clinical Medicine. 2022; 11(6): 1579 | | [Pubmed] | [DOI] | | | 8 |
Transcriptomics Analysis Indicates Trifarotene Reverses Acne-Related Gene Expression Changes |
|
| Brigitte Dreno, Rajeev Chavda, Valerie Julia, Amir Khammari, Sandrine Blanchet-Réthoré, Jayendra Kumar Krishnaswamy | | Frontiers in Medicine. 2021; 8 | | [Pubmed] | [DOI] | | | 9 |
Heat-killed Propionibacterium acnes augment the protective effect of 28-kDa glutathione S-transferases antigen against Schistosoma mansoni infection |
|
| Ho Yin Pekkle Lam, Ting-Hua Yang, Ting-Ruei Liang, Po-Ching Cheng, Kai-Chih Chang, Shih-Yi Peng | | Acta Tropica. 2021; 222: 106033 | | [Pubmed] | [DOI] | | | 10 |
Elucidating the immune infiltration in acne and its comparison with rosacea by integrated bioinformatics analysis |
|
| Lu Yang, Yan-Hong Shou, Yong-Sheng Yang, Jin-Hua Xu, Deyu Fang | | PLOS ONE. 2021; 16(3): e0248650 | | [Pubmed] | [DOI] | | | 11 |
Environmental, inflammatory, and anti-inflammatory squad in acne vulgaris pathogenesis: AhR, IL-36, and IL-38 |
|
| Fatma Mohamed El Esawy, Shuzan Ali Mohammed, Ebtesam Nasar Zargon Nasar, Sara Hemdan Mostafa, Doaa M. Elhabak | | Journal of Cosmetic Dermatology. 2021; | | [Pubmed] | [DOI] | | | 12 |
Modern Outlooks on Pathogenesis, Clinical Picture, Diagnosis and Management of Acne Vulgaris in Children and Adolescents |
|
| Elena R. Araviiskaia, Nikolay N. Murashkin, Leyla S. Namazova-Baranova, Roman A. Ivanov | | Current Pediatrics. 2020; 19(6): 408 | | [Pubmed] | [DOI] | | | 13 |
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis |
|
| Ana B. Pavel, Teresa Song, Hyun-Je Kim, Ester Del Duca, James G. Krueger, Celina Dubin, Xiangyu Peng, Hui Xu, Ning Zhang, Yeriel D. Estrada, Louis Denis, Niranjan Rao, Sandeep Gupta, David J. Zammit, Robert Bissonnette, Emma Guttman-Yassky | | Journal of Allergy and Clinical Immunology. 2019; 144(4): 1011 | | [Pubmed] | [DOI] | | | 14 |
Association of interleukin-6 gene promoter polymorphism with acne vulgaris and its severity |
|
| M. Ragab, E. M. Hassan, D. Elneily, N. Fathallah | | Clinical and Experimental Dermatology. 2019; 44(6): 637 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 6184 | | | Printed | 141 | | | Emailed | 0 | | | PDF Downloaded | 161 | | | Comments | [Add] | | | Cited by others | 14 | | |
|
|
